Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-x24gv Total loading time: 0 Render date: 2024-05-15T14:17:00.972Z Has data issue: false hasContentIssue false

Chapter 33 - Pheochromocytoma

from Section 9 - Endocrinology

Published online by Cambridge University Press:  05 September 2013

Michael F. Lubin
Affiliation:
Emory University, Atlanta
Thomas F. Dodson
Affiliation:
Emory University, Atlanta
Neil H. Winawer
Affiliation:
Emory University, Atlanta
Get access

Summary

Pheochromocytomas are not a common medical/surgical problem. They are estimated to cause only 0.1–0.5% of all cases of hypertension [1,2], and are seen in 4–7% of patients with incidentally found adrenal adenomas [2,3]. That being said, at some time in their careers medical consultants are likely to be asked to evaluate a patient with a suspected pheochromocytoma. Because catecholamines have major regulatory effects on many different body systems, it is vital that these be anticipated and properly managed in the perioperative period. Pheochromocytomas are associated with an increased risk of adverse reactions to many commonly prescribed drugs and clinicians must also be aware of this potential hazard. The removal of a pheochromocytoma has great potential for complications, both during and after surgery because of the release of catecholamines during manipulation or stimulation of the tumor.

Pathophysiology

Pheochromocytomas arise from chromaffin cells of the neural crest that migrate to form the adult adrenal medulla and sympathetic ganglia. These cells synthesize catecholamines through a series of enzymatically controlled steps, starting with the conversion of tyrosine to dihydroxyphenylalanine (dopa) by tyrosine hydroxylase. This is the rate-limiting step in catecholamine synthesis. Dopa is then converted to dopamine, which is subsequently decarboxylated to norepinephrine. The methylation of norepinephrine to epinephrine is accomplished through the action of phenylethanolamine-N-methyl transferase, an enzyme that is induced by glucocorticoids that reach the adrenal medulla in high concentrations through the corticomedullary venous sinuses from the adrenal cortex. Norepinephrine and epinephrine are the major products of most pheochromocytomas [4]. Epinephrine is produced mainly in the adrenal medulla; thus, a pheochromocytoma that produces epinephrine is nearly always located in the adrenal gland. Norepinephrine is produced and secreted in the central nervous system and the sympathetic post-ganglionic nerve endings as well as in the adrenal medulla. Dopamine is also produced and secreted by some pheochromocytomas. The metabolism of catecholamines takes place mostly in the same cells where the catecholamines are synthesized [4]. Once catecholamines reach the plasma, they have a half-life of only 1–2 minutes before they are taken up by cells or enzymatically degraded [5]. Metanephrine, normetanephrine, and vanillylmandelic acid are the major metabolites.

Type
Chapter
Information
Medical Management of the Surgical Patient
A Textbook of Perioperative Medicine
, pp. 373 - 376
Publisher: Cambridge University Press
Print publication year: 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Omura, M, Saito, J, Yamaguchi, K, Kakuta, Y, Nishikawa, T.Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 2004; 27: 193–202.CrossRefGoogle ScholarPubMed
Streeten, DH, Anderson, GH, Elias, MF.Prevalence of secondary hypertension and unusual aspects of the treatment of hypertension in elderly individuals. Geriatr Nephrol Urol 1992; 2: 91–8.CrossRefGoogle Scholar
Bernini, GP, Vivaldi, MS, Argenio, GF et al. Frequency of pheochromocytoma in adrenal incidentalomas and utility of the glucagon test for the diagnosis. J Endocrinol Invest 1997; 20: 65–71.CrossRefGoogle ScholarPubMed
Eisenhofer, G, Huynh, TT, Hiroi, M, Pacak, K.Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma. Rev Endocr Metab Disord 2001; 2: 297–311.CrossRefGoogle ScholarPubMed
Goldstein, DS, Cannon, RO, Quyyumi, A et al. Regional extraction of circulating norepinephrine, DOPA, and dihydroxyphenylglycol in humans. J Auton Nerv Syst 1991; 34: 17–35.CrossRefGoogle ScholarPubMed
Kantorovich, V, Eisenhofer, G, Pacak, K.Pheochromocytoma: an endocrine stress mimicking disorder. Ann NY Acad Sci 2008; 1148: 462–8.CrossRefGoogle ScholarPubMed
Manger, WM.The protean manifestations of pheochromocytoma. Horm Metab Res 2009; 41: 658–63.CrossRefGoogle ScholarPubMed
Manger, WM.An overview of pheochromocytoma: history, current concepts, vagaries, and diagnostic challenges. Ann NY Acad Sci 2006; 1073: 1–20.CrossRefGoogle ScholarPubMed
Barron, J.Phaeochromocytoma: diagnostic challenges for biochemical screening and diagnosis. J Clin Pathol 2010; 63: 669–74.CrossRefGoogle ScholarPubMed
Eisenhofer, G, Lenders, JW, Timmers, H et al. Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem 2011; 57: 411–20.CrossRefGoogle ScholarPubMed
Oliva, R, Angelos, P, Kaplan, E, Bakris, G.Pheochromocytoma in pregnancy: a case series and review. Hypertension 2010; 55: 600–6.CrossRefGoogle ScholarPubMed
Manger, W, Gifford, RW.Pheochromocytoma: current diagnosis and management. Cleve Clin J Med 1993; 60: 365–78.Google ScholarPubMed
Kopetschke, R, Slisko, M, Kilisli, A et al. Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. Eur J Endocrinol 2009; 161: 355–61.CrossRefGoogle ScholarPubMed
Brouwers, FM, Eisenhofer, G, Lenders, JW, Pacak, K.Emergencies caused by pheochromocytoma, neuroblastoma, or ganglioneuroma. Endocrinol Metab Clin North Am 2006; 35: 699–724.CrossRefGoogle ScholarPubMed
Jabbour, SA, Davidovici, BB, Wolf, R.Rare syndromes. Clin Dermatol 2006; 24: 299–316.CrossRefGoogle ScholarPubMed
Eisenhofer, G, Goldstein, DS, Walther, MM et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab 2003; 88: 2656–66.CrossRefGoogle ScholarPubMed
Lenders, JW, Pacak, K, Walther, MM et al. Biochemical diagnosis of pheochromocytoma: which test is best?J Am Med Assoc 2002; 287: 1427–34.CrossRefGoogle ScholarPubMed
Grossman, A, Pacak, K, Sawka, A et al. Biochemical diagnosis and localization of pheochromocytoma: can we reach a consensus?Ann NY Acad Sci 2006; 1073: 332–47.CrossRefGoogle ScholarPubMed
Unger, N, Pitt, C, Schmidt, IL et al. Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass. Eur J Endocrinol 2006; 154: 409–17.CrossRefGoogle Scholar
Henry, JB, ed. Adrenal gland. In Clinical Diagnosis and Management by Laboratory Methods. 20th edn. Philadelphia, PA: W. B. Saunders; 2001, p. 313.Google Scholar
Bravo, EL.Pheochromocytoma. Cardiol Rev 2002; 10: 44–50.CrossRefGoogle ScholarPubMed
Lenders, JW, Pacak, K, Huynh, TT et al. Low sensitivity of glucagon provocative testing for diagnosis of pheochromocytoma. J Clin Endocrinol Metab 2010; 95: 238–45.CrossRefGoogle ScholarPubMed
Johnson, PT, Horton, KM, Fishman, EK.Adrenal mass imaging with multidetector CT: pathologic conditions, pearls, and pitfalls. Radiographics 2009; 29: 1333–51.CrossRefGoogle ScholarPubMed
Zeiger, MA, Thompson, GB, Duh, QY et al. The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. Endocr Pract 2009; 15 (Suppl 1): 1–20.CrossRefGoogle Scholar
Hamrahian, AH, Ioachimescu, AG, Remer, EM et al. Clinical utility of noncontrast computed tomography attenuation value (Hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience. J Clin Endocrinol Metab. 2005; 90: 871–7.CrossRefGoogle ScholarPubMed
Elsayes, KM, Menias, CO, Siegel, CL et al. Magnetic resonance characterization of pheochromocytomas in the abdomen and pelvis: imaging findings in 18 surgically proven cases. J Comput Assist Tomogr 2010; 34: 548–53.CrossRefGoogle ScholarPubMed
Jalil, ND, Pattou, FN, Combemale, F et al. Effectiveness and limits of preoperative imaging studies for the localization of pheochromocytomas and paragangliomas: a review of 282 cases. Eur J Surg 1998; 164: 23–8.CrossRefGoogle Scholar
Pacak, K, Eisenhofer, G, Ahlman, H et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. Nat Clin Pract Endocrinol Metab 2007; 3: 92–102.CrossRefGoogle ScholarPubMed
Weingarten, TN, Cata, JP, O'Hara, JF et al. Comparison of two preoperative medical management strategies for laparoscopic resection of pheochromocytoma. Urology 2010; 76: 508.e6–11.CrossRefGoogle ScholarPubMed
Kohl, BA, Schwartz, S.How to manage perioperative endocrine insufficiency. Anesthesiol Clin 2010; 28: 139–55.CrossRefGoogle ScholarPubMed
Roizen, MF, Schreider, BD, Hassan, SZ.Anesthesia for patients with pheochromocytoma. Anesthesiol Clin North Am 1987; 75: 269–75.Google Scholar
van der Horst-Schrivers, AN, Kerstens, MN, Wolffenbuttel, BH.Preoperative pharmacological management of phaeochromocytoma. Neth J Med 2006; 64: 290–5.Google ScholarPubMed
Chen, H, Sippel, RS, O'Dorisio, MS et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 2010; 39: 775–83.CrossRefGoogle ScholarPubMed
McMillian, WD, Trombley, BJ, Charash, WE, Christian, RC.Phentolamine continuous infusion in a patient with pheochromocytoma. Am J Health Syst Pharm 2011; 68: 130–4.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×